Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
about
Trovafloxacin is active against Toxoplasma gondiiPharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.The new fluoroquinolones: A critical reviewEfficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administrationInter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilitiesSingle-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate.Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.
P2860
Q28379193-F59129F9-50F9-4834-824C-58A8E0F82180Q33695030-89DCC85A-541F-4F21-B05D-60FDBCDDDBD3Q33976236-323FF839-C594-4B83-A731-D4E3F0238477Q33979516-08A95A60-8E7A-4E38-8F7F-1F3600F17FCDQ34098582-0A01B8BE-CE1D-4D6E-92C1-66CC01DA1C7BQ34746644-89203D5F-6CA0-443B-BCB2-D27B5C2E6771Q35649595-2A1DCA8C-82DE-4245-B828-B5A4F63230D4Q39469535-A8231085-5D94-4A8A-8DEA-8050BDF58A80Q39470200-2C11A475-F32A-4976-B397-ED8D85934E18Q39471033-02D5FDB2-B531-4BE4-9DCD-44E77251F2A5Q39557221-6DDB0179-280D-4F43-BC86-C6F9B34A4140Q39559370-A3441986-0003-4EE0-AA83-3B7ADF67A1A1Q39651041-B52267EF-863B-4A26-9644-82ADE8A52F35Q42588154-22C39601-6E14-4F14-A3B6-1C86208FA981
P2860
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
@ast
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
@en
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
@nl
type
label
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
@ast
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
@en
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
@nl
prefLabel
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
@ast
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
@en
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219)
@en
P2093
P2860
P356
10.1128/AAC.40.1.47
P407
P577
1996-01-01T00:00:00Z